top of page


CALLS TO ACTION

FDA: IRB Waiver of Informed Consent in Human Clinical Trials
Issued a Call to Action, asking our members, to send a copy of our correspondence to the FDA outlining our concerns with the issuance of an IRB Waiver/Alteration of Informed Consent for Human Clinical Trials issued in 2017.

FDA Attorney Response to Inquiry Regarding Issuance of the IRB Waiver/Alternation of Informed Consent for Human Clinical Trials
Issued a Call to Action, asking members to contact their lawmakers and request support for the FDA to put the IRB Waiver/Alternation of Informed Consent for Human Clinical Trials, regulatory change, on the Federal Register to permit the collection of public feedback, post-fact. This should have taken place in 2017 when the change was issued. Given the gravity of this change, the public should have been permitted the opportunity to provide their feedback.

National Campaign - Opioid Supply Chain
Issued a Call to Action, asking our members, to forward our correspondence to the DEA too their federal lawmakers, asking for their support for the creation of a federal committee to review the supply chain issues related to opioid analgesics medications, and for the development of policy recommendations to address any gaps or inconsistencies in current policy guidance.

FDA Public, Private-Partnership with Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
Issued a Call to Action, asking our members to forward our correspondence to their lawmakers, asking for their support for the FDA and its partners, to provide the public transparency on their activities.
bottom of page